Keampferol-3-O-rhamnoside abrogates amyloid beta toxicity by modulating monomers and remodeling oligomers and fibrils to non-toxic aggregates by Md Sharoar et al.
Sharoar et al. Journal of Biomedical Science 2012, 19:104
http://www.jbiomedsci.com/content/19/1/104RESEARCH Open AccessKeampferol-3-O-rhamnoside abrogates amyloid
beta toxicity by modulating monomers and
remodeling oligomers and fibrils to non-toxic
aggregates
Md Golam Sharoar1,4*, Arjun Thapa5, Mohammad Shahnawaz6, Vijay Sankar Ramasamy1, Eun-Rhan Woo3,
Song Yub Shin1,2 and Il-Seon Park1,2*Abstract
Background: Aggregation of soluble, monomeric β- amyloid (Aβ) to oligomeric and then insoluble fibrillar Aβ is a
key pathogenic feature in development of Alzheimer’s disease (AD). Increasing evidence suggests that toxicity is
linked to diffusible Aβ oligomers, rather than to insoluble fibrils. The use of naturally occurring small molecules for
inhibition of Aβ aggregation has recently attracted significant interest for development of effective therapeutic
strategies against the disease. A natural polyphenolic flavone, Kaempferol-3-O-rhamnoside (K-3-rh), was utilized to
investigate its effects on aggregation and cytotoxic effects of Aβ42 peptide. Several biochemical techniques were
used to determine the conformational changes and cytotoxic effect of the peptide in the presence and absence of
K-3-rh.
Results: K-3-rh showed a dose-dependent effect against Aβ42 mediated cytotoxicity. Anti-amyloidogenic properties
of K-3-rh were found to be efficient in inhibiting fibrilogenesis and secondary structural transformation of the
peptide. The consequence of these inhibitions was the accumulation of oligomeric structural species. The
accumulated aggregates were smaller, soluble, non-β-sheet and non-toxic aggregates, compared to preformed
toxic Aβ oligomers. K-3-rh was also found to have the remodeling properties of preformed soluble oligomers and
fibrils. Both of these conformers were found to remodel into non-toxic aggregates. The results showed that K-3-rh
interacts with different Aβ conformers, which affects fibril formation, oligomeric maturation and fibrillar stabilization.
Conclusion: K-3-rh is an efficient molecule to hinder the self assembly and to abrogate the cytotoxic effects of
Aβ42 peptide. Hence, K-3-rh and small molecules with similar structure might be considered for therapeutic
development against AD.
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Alzheimer’s disease (AD) is characterized by progressive
and insidious neurodegeneration of the central nervous
system, which eventually leads to a gradual decline of
cognitive function and dementia [1]. The principal
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reproduction in any medium, provided the orintracellular neurofibrillary tangles and extracellular de-
position of amyloid beta (Aβ) peptides in the form of se-
nile plaques [2]. The peptide is derived from amyloid
precursor protein (APP) by sequential cleavage of α-, β-,
and γ- secretases [3]. Differential cleavage by γ-secretase
is one factor contributing to formation of Aβ with differ-
ent C-termini. Among the two most common alloforms
of Aβ, Aβ40 (ending at Val at 40 position) and Aβ42
(ending at Ala at 42 position), the longer form(Aβ42) is
more prone to aggregation than the shorter form(Aβ40),
and is the main constituent of senile plaques [4].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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formational changes to form β-sheets rich insoluble fi-
bril through fibrillization process. Fibrillization follows
nucleation-dependent aggregation, which basically com-
prises two phases; nucleation, the formation of the nu-
cleus by association of a series of monomeric peptides
[5], and extension, the subsequent addition of mono-
mers to the end of the existing nucleus [6]. However, Aβ
fibrillization derives several transitional species including
trimer, pentamer, or higher molecular weight complex, also
known as Aβ -derived diffusible ligands (ADDLs) [7], oli-
gomers composed of 15–20 monomers [8], protofibrils
(string of oligomers) [9], and dodecameric oligomers Aβ
*56 [10]. All of these unstable intermediates are collectively
designated as “soluble Aβ” [11]. Recent studies have
reported that the soluble Aβ oligomers formed during early
aggregation are the main cytotoxic agents rather than
monomeric or fibrilar forms [12]. Therefore, preventing
the assembly of Aβ monomer into toxic oligomer or fibril
is the primary goal of a number of therapeutic strategies
under development or in clinical trials. Hence, major re-
search has involved the development of compounds cap-
able of inhibiting or reversing the Aβ aggregation process.
Thus far, a number of diverse compounds including small
molecules [13,14], antibodies [15], peptidic β-sheet break-
ers [16,17], and osmolytes [18], have been used to prevent
or to reduce the aggregation of Aβ into oligomers or fibrils.
Small molecules have been reported to inhibit single or
multiple steps of the Aβ fibrillization process [19]. In
addition, small molecules that efficiently inhibit the early
steps of Aβ fibrillogenesis and stabilize its nontoxic confor-
mations have been considered as possible AD therapeutics,
because the self-assembly of the peptide is directly linked
to the pathogenesis of AD. Among the Aβ interacting
small molecules, curcumin is one of the most attractive
compounds to scientists due to its direct capability to bind
with small Aβ species, to block aggregation and fibril for-
mation and to disaggregate mature fibrils under both
in vitro and in vivo conditions [20]. Other Aβ binding
molecules includes sulfonate dye Congo red [21] and thio-
flavin T(ThT) [22], which are utilized as classic reagents
for determination of characteristic β-sheet mediated fibrilli-
zation. In fact, the most of reported small molecule Aβ
inhibitors are structurally similar to Congo red and ThT, in
that they are planar and aromatic compounds.
Flavonoids, found ubiquitously in plants, are the most
common polyphenolic compounds group in human diet
form [23]. This group of compounds has several benefi-
cial effects on human health such as anti-oxidant [24],
anti-allergic, anti-cancer and anti-inflammatory [25], and
anti-microbial [26] activities. Flavonoids are also reported
to decrease the risk of age related dementia [27]. Extensive
studies on Ginkgo biloba extracts HE208 [28] and EGb
761 [29] indicate that the flavonoid molecules are essentialfor anti-amyloidogenic and anti-apoptotic activity in
neural cells. A number of isolated flavonoids have been
found to be effective against oligomer formation, fibril
stabilization and cytotoxic effects of Aβ peptide [30-34].
On the other hand, some polyphenoles are reported to be
inhibited Aβ fibrilogenesis, but not Aβ mediated cytotox-
icity, while others described as cytoprotective, but not
antifibrillogenic against Aβ [35,36]. Hence, the correlation
of anti-amyloidogenic activity and anti-cytotoxic effect of
flavonoids remains unclear. In the current study, we
screened several phenolic compounds against cytotoxic
effects of Aβ peptide. We identified a polyphenolic glyco-
side flavone, Keampferol-3-rhamnoside (K-3-rh), as an
effective molecule for alteration of the on pathway aggre-
gation of different Aβ conformers to off pathway non-




K-3-rh, quercitrin (Q) and keampferol-3-rutinoside (K-3-
ru) were purchased from Sigma (St. Louis, USA). Gallic
acid (GA), protocatechuic acid (PA), gallic acid methyl
ester (GAME), quercetin dihydrate (Quer-di-hy), quer-
cetin hydrate (Quer-hy) and kaempferol (K) are isolated
as described earlier [37]. Fetal Bovine Serum (FBS) was
purchased from Life Technology Inc. (Grand Island,
USA). Dulbecco’s modified Eagles medium, Ham’s F 12
(1:1) (DMEM/F-12) was obtained from Welgene (Daegu,
Korea). Western blotting detection kit (WEST-ZOL plus)
was purchased from iNtron Biotechnology (Gyeonggi-do,
Korea). Phosphate buffered saline (PBS) was purchased
from Amresco (Solon, USA). Monoclonal anti-Aβ antibody
6E10 was acquired from Signet Laboratories (Dedham,
USA). Urea was obtained from USB chemicals and aceto-
nitrile was from Merck (Darmstadt, Germany). All other
chemicals were obtained from Sigma (St. Louis, USA), un-
less otherwise stated.
Preparation of amyloid beta
Amyloid beta peptides were expressed in E.coli as fusion
proteins and purified as described before [38]. The
purified peptides were solubilized in 100% 1,1,1,3,3,3,-
hexafluoro-2-propanol, and dried under nitrogen flow
and subsequently, under a vacuum for 30 min. The pep-
tide aliquots were stored at −20°C until use. Immediately
before use, the peptides were dissolved in 0.1% NH4OH
at a concentration of 2 mg/ml followed by bath sonic-
ation for 10 min at 4°C. The solution was diluted at the
desired concentration with PBS. Aβ42 oligomers and
fibrils were prepared as described earlier [39] with little
modification. Briefly, oligomers were prepared by dilut-
ing the peptides in cell culture media at a concentration
of 100 μM, vortexing for 30 seconds and incubating at
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prepared by co-incubating Aβ42 (20 μM) and 40 μM K-3-
rh for 12 h and centrifuging the sample to obtain the
supernatant. To make fibrils, Aβ42 (100 μM) was incu-
bated in the presence of 0.02% sodium azide in PBS at
37°C for four days. The samples were then centrifuged at
16000 × g for 30 min. The pellet fraction (fibrils) was
washed three times with PBS. Fibrils were sonicated for
10 min, quantified using the Bradford method and used
immediately or stored at −80°C.Cell culture and cell death assay
Human neuroblastoma SH-SY5Y was cultured in Dul-
becco’s Modified Eagles medium and Ham’s F 12 (1:1),
supplemented with 10% (v/v) fetal bovine serum (FBS)
and 1% antibiotics, at 37°C under 5% CO2. Cells were
seeded at a density of 15,000 cells/well in 96-well plates
(Nunc, Denmark) and incubated for 24 h. The media
were replaced with serum-free media and cells were
further cultured for 24 h. For measurement of cell death,
cells were treated with indicated concentrations of
different Aβ conformers in the presence or absence of
flavonoid(s) for 12 or 24 h. Cell viability was assessed by
MTT reduction assay. Briefly, 20 μl of 5 mg/ml MTT so-
lution in PBS was added to each well and incubated for
2 h. Then, 100 μl of solubilization buffer [20% SDS solu-
tion in 50% (v/v) DMF (pH 4.7)] was added to each well.
The absorbance was recorded after 12–16 h at 570 nm
using a micro plate reader Spectra Max 190 (Molecular
Devices, CA, USA).Thioflavin-T (Th-T) assays
For the polymerization assay, Aβ42 (20 μM) was incubated
in PBS at 37°C in the presence or absence of K-3-rh in a
final volume of 30 μl without shaking. Twenty μl from each
reaction was mixed with 80 μl of 5 μM Th-T in PBS solu-
tion. Fluorescence was measured on a microplate spectro-
fluorometer Gemini-XS (Molecular Devices CA, USA)
using excitation at 440 nm and emission at 490 nm [39].
Th-T fluorescence representing the characteristic sigmoidal
curve was plotted as common logarithms in the equation:
log [F (t)/ A−F (t)] = at+ b, where t is the reaction time,
F(t) is the fluorescence as a function of time, A is tenta-
tively determined as F (∞), a slope and b is the y- intercept
[40]. Differentiating the above equation by t and subse-
quent rearrangement produced a logistic equation, F’ (t) =
BF (t) [A−F (t)], where, B = a ln 10 A / 2, and F’(t) repre-
sents rate of fluorescence increase at a given time. When F
(t) =A/2, F(t)/ A−F(t) = 1 and F’(t) reaches its maximum.
This time point was referred to as t / 2 [40]. For the Aβ42
fiber extension assay, fresh Aβ42 (20 μM) was incubated
with preformed Aβ42 fibrils (1.1 μM) in the presence of
varying concentrations of K-3-rh. For the fibrildestabilization assay, preformed Aβ42 fibrils (20 μM) were
incubated in presence of varying concentrations of K-3-rh.
Circular dichroism (CD) spectroscopy
Aβ42 (20 μM) was incubated in PBS at 37°C either alone
or in the presence of 20 μM of K-3-rh for 0 or 12 h. CD
spectra [41] were recorded using a 1-mm path length
cuvette at 0.5 nm intervals between 190 nm and 250 nm
at 1 nm resolution with a scan rate of 50 nm/min using
a Jasco Sectropolarimeter (Jasco Co., Tokyo, Japan) at
25°C. Average was taken from five scans for each sample.
Aβ spectra were obtained by subtracting buffer back-
ground. Background spectra given by K-3-rh alone under
identical conditions were subtracted from Aβ samples
incubated in the presence of K-3-rh. The corrected, aver-
aged spectra were smoothed using the means-movement
algorithm in the Jasco spectra analysis program.
Transmission Electron Microscopy (TEM)
Twenty μM native Aβ42, oligomeric Aβ42(OAβ42) or
fibrilar Aβ42(fAβ42) either alone or in the presence of
K-3-rh was incubated in PBS at 37°C for 12 h. Five μl of
sample was adsorbed on Formvar-coated 200-mesh
nickel grids for 30 min and extra solution was wiped off
[42]. The grids were negatively stained with 2% uranyl
acetate for 1 min and washed at least three times with
distilled water. The samples were then analyzed using
transmission electron microscopy (Hitachi, Japan) at an
accelerating voltage of 80 kV at magnification of 40,000x.
Detection of Aβ structural species by immunoblotting
Twenty μM native Aβ42 was incubated in PBS at 37°C
without or with indicated amounts of K-3-rh for 12 and
24 h. 2 μl from each reaction mixture was diluted with
8 μl or 6 μl (for cross link reaction) of PBS. For control
(0 h) fresh Aβ42 was diluted to a concentration of 20 μM
in PBS and from there 2 μl was taken. 2 μl of SDS buffer
[50 mM Tris buffer (pH 6.8), 10% glycerol, 2% SDS, and
0.1% β-mercaptoethanol] was then added to each sample.
Crosslinking of the peptide in the reaction mixture was
performed as described previously [43], with slight modifi-
cation. Briefly, before addition of SDS buffer, each sample
was incubated with 0.01% glutaraldehyde (v/v) in PBS
(2 μl from a 0.05% stock solution) for 10 min. The cross-
linking reaction was then terminated with an equal
volume of SDS buffer. Samples were then run on a SDS-
PAGE gel (16% acrylamide) without boiling. Subsequently,
the peptide was transferred to polyvinylidene difluoride
(PVDF) membrane. After blocking with 5% milk in Tris-
buffered saline containing 0.2% (v/v) Tween 20 at room
temperature for 1 h, the membranes were probed with
anti-Aβ antibody 6E10 (1:10,000). The blots were then
incubated with horseradish peroxidase-conjugated Ig anti-
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developed using a West-zol plus kit.
Statistical analysis
All experiments were performed in triplicate. For each
experiment, data are expressed as the mean ± standard
error (SE, n = 3) and statistical significance was assessed
by one-way analysis of variance (ANOVA) and Student’s
t-tests. A p value of <0.05 was considered significant.
Results
K-3-rh and related flavonoids are cytoprotective against
Aβ42 toxicity
Flavonoids are suggested to be neuroprotective against
several stress or toxic compounds. In the current study,
first we screened nine available phenolic compounds
(Figure 1) for their protective effects against Aβ42 tox-
icity to human neuroblastoma SH-SY5Y cells. Treatment
with 20 μM of the peptide for 12 h resulted in a decrease
of cell viability to ~50%. The most of the flavonoids
(20 μM) enhanced cell viability to different extents
(Figure 2A). Cell viability enhancement of approximately













































































































Figure 1 Chemical structures of flavonoids: structures of K-3-rh and oand K. Treatment with compounds such as Q, GAME,
and Quer-di-hy alone was found to result in decreased
cell viability (Figure 2A). Notably, the most of the poly-
phenolic flavonoids (Figure 1) found to be more effective
than monophenolic compounds for protection of cells
against Aβ toxicity (Figure 2A).
Cytoprotective effects of the flavonoids, which showed
better efficiency in inhibition of Aβ induced cell death
(Figure 2A) and are relatively similar structurally (Figure 1),
were further explored for their dose-dependent conse-
quence (Figure 2B). Cell survival was found to be enhanced
by increasing the concentration of K-3-rh, where 20 μM of
the compound enhanced 30% cell survival (Figure 2B). On
the other hand, dose-dependent effects on protection of
cells against Aβ toxicity were found to be flattened at
> 20 μM for Q and K-3-ru (Figure 2B). This might be due
to the toxic effect of Q and K-3-ru on cells, because both
of these chemicals were found to decrease cell survival at a
higher concentration when applied without Aβ (data not
shown). On the other hand, no toxic effect of treatment
with K-3-rh alone was observed, even at 50 μM (data not
shown). The EC50 values calculated as 14.82 ± 1.09, 23.10 ±


























































































































































(EC50 = 14.82 ± 1.09 µM)
(EC50 = 23.10 ± 7.60 µM)




Figure 2 Effects of flavonoids on Aβ42 induced cytotoxicity.
A. Cells were treated with monomeric Aβ42 (20 μM) for 12 h in the
absence or presence of 20 μM of kaempferol-3-O-rhamnoside (K-3-
rh), quercitrin (Q), kaempferol-3-O-rutinoside (K-3-ru), gallic acid (GA),
protocatechuic acid (PA), gallic acid methyl ester(GAME), quercetin
dihydrate(Quer-di-hy), quercetin hydrate (Quer-hy) and kaempferol
(K). B. Cells were exposed to monomeric Aβ42 (20 μM) in the
presence of 0–50 μM of indicated flavonoids for 12 h. Cell viability
was assessed using the MTT reduction assay. Error bars indicate the
standard deviation of triplicate independent experiments.
Significantly different from control without Aβ42 and with Aβ42 (0
flavonoid concentration) groups indicated as #p < 0.05 or ##p < 0.01
and *p < 0.05 or **p < 0.01, respectively.
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compound for protection against Aβ induced cell death.K-3-rh inhibits fibrilogenesis and secondary structural
transformation of Aβ42
To examine the effects of K-3-rh on fibril formation of
Aβ42, 20 μM of peptide was incubated in the presence
of several concentrations of K-3-rh and Th-T assay was
performed for measurement of fibrillogenesis activity.The fluorescence profiles of Aβ42 aggregation with in-
creasing K-3-rh concentrations are shown in Figure 3A.
Aβ42 alone showed a characteristic sigmoidal curve
when incubated at 37°C for 6 h [44]. In the presence of
0–50 μM K-3-rh, the final fluorescence level, indicative
of the amount of mature fibrils formed, showed a dose-
dependent decrease (Figure 3A). Semilogarithmic plots
of thioflavin T fluorescence versus time gave a linear re-
lationship for the indicated time (Figure 3B). From these
plots, t/2 values were obtained (see Materials and
Methods), which gives us information about the kinetics
of the nucleation step during the early stage of fibrillo-
genesis [40]. It is expected that the t/2 value would in-
crease if the flavonoids inhibited the nucleation process,
the rate-determining step of polymerization. t/2 values
for Aβ42 (20 μM) were calculated as 43.07, 45.76, 40.70,
39.22, 39.55 and 34.10 min. in the presence of 0, 5, 10,
20, 40 and 50 μM of K-3-rh, respectively. The small
changes of t/2 values in the presence of K-3-rh demon-
strated that the marginal effect of the flavonoid in the
nucleation step [40]. We also noticed the disappearance
of linearity at higher concentrations of flavonoids or
upon longer incubation times (Figure 3B), implying the
involvement of unidentified processes and, thus, render-
ing the logistic equation invalid.
The fibril extension experiment was performed by incu-
bating fresh Aβ42 (20 μM) with 1.1 μM preformed Aβ42
fibrils (seed), which showed an increase of fluorescence
hyperbolically without lag phase (Figure 3C) [40,44]. The
final equilibrium of the curve showed a dose-dependent
decrease in the presence of K-3-rh, indicating that the final
amount of fibrils formed is decreased in the presence of
the flavonoid in a concentration-dependent manner. Four
perfect linear logarithmical plots with deferent y intercept
were obtained by plotting logarithmic plots of fluores-
cence difference against times (Figure 3D). The initial
rates of Aβ fibril extension, the slopes of the linear portion
of the fluorescence profiles, showed a dose-dependent
decrease when co-incubated with K-3-rh (Figure 3E). The
IC50 value against fibril extension was found to be
~20 μM.
Structural transition to form a β-sheet structure is a char-
acteristic feature of Aβ fibrillogenesis [41]. To examine the
effect of K-3-rh on secondary structural transformation,
Aβ42 (20 μM) was incubated with or without K-3-rh
(40 μM) and the presence of β-sheet was detected by CD
spectroscopy. CD spectra of Aβ42 alone or with K-3-rh at
0 h, showed a negative absolute value at approximately
~200 nm, suggesting the presence of a largely unfolded
peptide at monomeric state with a significant level of ran-
dom coil (Figure 3F). Upon incubation for 12 h at 37°C, the
peptide alone exhibited the shift of a strong signal to nega-
tive ellipticity of ~220 nm, indicating the formation of β-





























































































Figure 3 K-3-rh inhibits polymerization, fibril extension and secondary structural transformation of Aβ42. A. Inhibition of Aβ42
polymerization. Aβ42 (20 μM) was incubated in PBS at 37°C in the presence of 0 (open circle), 5 (closed circle), 10 (open triangle), 20 (closed
triangle), 40 (open square) and 50 (closed square) μM K-3-rh for 0–6 h. IC50 was calculated as 30 μM. B. Logarithmic plot of F(t)/A−F(t) versus
reaction time obtained from polymerization assay. C. Inhibition of Aβ42 fibril extension. Fresh Aβ42 (20 μM) was added to 1.1 μM preformed
seed and incubated at 37°C in the presence of 0 (open circle), 10 (open triangle), 20 (closed triangle), and 40 (closed square) μM K-3-rh. IC50 value
was calculated as 20 μM. D. Logarithmic plot of A−F(t) versus reaction time obtained from the fibril extension assay. E. Effect of Aβ42
concentrations on the initial rate of Aβ42 fibril extension. F. Inhibition of β-sheet transformation of Aβ42. The peptide (20 μM) alone or in the
presence of K-3-rh (40 μM) was incubated in PBS at 37°C for 0 or 12 h as indicated. Spectra were obtained by subtracting buffer background as
described in Materials and Methods section.
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observed in the presence of 20 μM K-3-rh after an incuba-
tion period of 12 h (Figure 3F). The results suggest that K-
3-rh inhibits β-sheet formation of the peptide. All of these
data suggest that K-3-rh did not have a significant impact
on fibril nucleation during the lag phase (Figure 3A), how-
ever, once the rapid Aβ elongation phase was initiated,
the polyphenol inhibited Aβ fibrillogenesis efficiently
(Figure 3C and 3E), and it obstructed the secondary struc-
tural transition of the peptide to form β-sheet structures.K-3-rh causes accumulation of smaller Aβ42 aggregates
Polymerization, fibril extension and structural transition
studies have shown that K-3-rh inhibits formation of Aβ42
fibrils. The consequences of these inhibitions were charac-
terized by western blot analysis and TEM. In the immuno-
blot assay, we used Aβ-specific antibody 6E10. A chemical
cross-linker was also used to cross-link the Aβ species
(Figure 4C-D) prior to SDS-PAGE analysis in order to avoid
SDS-induced dissociation of oligomers [39], and compared
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Figure 4 Accumulation of Aβ42 aggregates in the presence of K-3-rh. Fresh Aβ42 (20 μM) was incubated in PBS at 37°C for 12 h (A and C)
or 24 h (B and D), either alone or in the presence of the indicated concentration of K-3-rh. After the incubations, the peptide in the reactions was
left uncrosslinked (A - B) or crosslinked (C - D) with 0.01% glutaraldehyde before being subjected to 16% SDS-PAGE and the following
immunoblotting with anti-Aβ antibody 6E10. Two μl of reaction mixture was loaded for SDS-PAGE. C indicates a fresh Aβ42 (no incubation) as
control. The numbers on the left indicate the relative molecular weights of protein markers. E. TEM study of the effects of K-3-rh on Aβ42
fibrillogenesis. Twenty μM fresh Aβ42 either alone (left) or in the presence of 20 μM (middle) or 40 μM (right) of K-3-rh were incubated in PBS at
37°C for 12 h. Aβ42 morphology was then visualized by TEM. Scale bar is shown at the bottom.
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appearance of almost all monomeric species (Figure 4A,
at the bottom of the gel). In the presence of different
concentrations of K-3-rh, monomeric predominant bands
were observed at the bottom of the gel along with bands
around the 20 kDa area of the gel (Figure 4A and 4C),
probably the intermediate aggregates of the fibrilogenesis
process. These intermediate species, straddling a wide
range of sizes, showed a significant increase at higher con-
centrations (20 μM or more) of flavonoid. In addition, the
larger aggregates were found to be enriched when incuba-
tion time was increased (Figure 4B), which was clearly
observed in crosslinked samples (Figure 4D). Disappear-
ance of monomeric Aβ42 and enrichment of aggregates of
several sizes in the presence of K-3-rh were obviously
noted upon increasing the incubation times (Figure 4Band 4D). This result suggests that accumulation of several
structural species of Aβ occured in the presence of K-3-
rh. The data are in good accordance with the earlier
reports where accumulations of Aβ oligomers have been
observed in the presence of polyphenolic inhibitors
[39,45].
The above results indicate that K-3-rh causes accumu-
lation of several intermediates including larger aggre-
gates to small oligomeric species. To confirm the findings,
the incubated samples were imaged using TEM in order to
visualize the accumulated species. Aβ42 (20 μM) incubated
alone at 37°C for 12 h, predominantly composed of typical
fibrils (Figure 4E, left panel). In the presence of K-3-rh,
however, fibrilar structure was absent, instead, small spher-
ical shaped and some branched structures were observed
(Figure 4E, middle and right panels). The morphology and






































Figure 5 Biochemical characterization of accumulated Aβ42
species. A. Immunoblot analysis of Aβ42 oligomers probed with the
6E10 monoclonal antibody: lane 1, fresh Aβ42 as a control; lane 2,
K-3-rh accumulated Aβ42 oligomers, obtained in soluble fraction by
centrifuging Aβ42(20 μM) and K-3-rh(40 μM) preincubated(12 h)
sample; lane 3, Aβ42 of lane 2 cross-linked before the immunoblot
assay; lane 4, Aβ42 subjected to the oligomerization process and
recovered in the soluble fraction after centrifugation of the mixture
(Aβ42 preformed oligomers); lane 5, Aβ42 of lane 4 cross-linked
before the immunoblot assay. B. Thioflavin T assay of fresh
monomeric Aβ42 as control (Mono - white bar), K-3-rh accumulated
Aβ42 oligomers (K-3-rh Oligo - light gray bar), Aβ42 preformed
oligomers (Oligo - dark gray bar) and Aβ42 mature fibrils (Fibril -
black bar). C. Decrease of the viability of SH-SY5Y cells (referred to as
% of cell death) by Aβ42 preformed oligomers (Oligo - dark gray
bar), K-3-rh accumulated Aβ42 oligomers (K-3-rh Oligo - light gray
bar) and 20 μM Aβ42 pre-incubated in the absence (Aβ - white bar)
or in the presence of 40 μM K-3-rh (Aβ + K-3-rh - black bar) for 12 h.
Error bars indicate the standard deviation of triplicate independent
experiments and ** indicate significant different between the groups
at p < 0.01.
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mediate species previously reported [19,46,47]. The data
clearly support the presence of different oligomeric species
in Aβ samples incubated with K-3-rh.
K-3-rh modulated Aβ oligomers are soluble, non-toxic off-
pathway aggregates
The above results indicated that K-3-rh inhibits fibrillo-
genesis and β-sheet formation of Aβ42 peptide. Suppres-
sion of Aβ induced cell death in the presence of K-3-rh
might be due to these inhibitory processes. On the other
hand, inhibitory effects of K-3-rh also modulated several
oligomeric intermediates of the peptide (See Figure 4A-E),
and the soluble oligomeric Aβ are reported to be more
toxic than fresh or fibrilar Aβ [48,49]. Hence, we charac-
terized the K-3-rh accumulated oligomers in order to de-
fine their size, structure and cytotoxic properties. First, we
obtained the supernatant by centrifuging the Aβ sample
preincubated with K-3-rh (40 μM) for 12 h at 37°C. We
termed this soluble fraction of Aβ42 as “K-3-rh accumu-
lated oligomers (K-3-rh oligo)”, which were then analyzed
and compared with the preformed toxic oligomers [39].
K-3-rh accumulated soluble Aβ42 was enriched with
mostly smaller aggregates, which was observed as the pre-
dominant bands around the <7 kDa and <20 kDa areas of
the gel (Figure 5A, lanes 2 and 3). On the other hand,
mostly larger species with a size range of ~20 kDa to
>100 kDa were visualized in preformed oligomeric Aβ42
(Figure 5A, lane 4 and 5). Both oligomers were Th-T nega-
tive (Figure 5B), indicating the absence of β-sheet fibrils
among them. While, the inductions of cell death by the oli-
gomers were incomparable (Figure 5C), where preformed
oligomers killed ~55% of cells and K-3-rh accumulated oli-
gomers induced only ~7% cell death, suggesting the non-
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noted that, a very small amount of Aβ was found as
precipitate during the preparation of a soluble fraction of
K-3-rh pre-incubated sample, which may decrease the Aβ
concentration in the supernatant. To avoid the variation of
Aβ42 concentration and effects of precipitate Aβ42, the
preincubated whole samples were also included for meas-
urement of cell death, which also showed a comparable re-
sult (~9% cell death by Aβ42 preincubated in the presence
of K-3-rh for 12 h) with supernatant sample (Figure 5C).
All of these data indicate that K-3-rh modulates the Aβ42
to soluble non-toxic smaller aggregates. The results are in
good accordance with our previous report that the poly-
phenolic flavonoids cause the accumulation of off pathway
oligomers [39].
K-3-rh remodels soluble toxic Aβ oligomers and pre-
formed fibrils to non-toxic smaller aggregates
Our results described above suggest that K-3-rh effect-
ively obstructs the Aβ aggregation pathway and modulate
to off pathway non-toxic aggregates. Next, we attempt to
determine whether the flavonoid is effective for remodel-
ing of the toxic soluble oligomers and mature fibrils. We
used preformed soluble oligomers and fibrils as described
in the Materials and Methods section, and characterized
their aggregation and cytotoxic properties in the absence
or presence of K-3-rh.
The preformed oligomers were Th-T negative and
stable for longer than 12 h, which converted to Th-T
positive fibrillar structure when incubated for 24 h at
37°C (Figure 6A, gray bar and 6B, left and middle panel).
In the presence of 40 μM K-3-rh, the oligomers were
found to be Th-T negative (Figure 6A, black bar) and
had mostly smaller globular structure (Figure 6B, right
panel). Similarly, K-3-rh was also found to disaggregate
the mature fibrils in a dose-dependent manner when co-
incubated with K-3-rh for 12 h (Figure 6C). The IC50
value for the disestablishing properties of these fibrils
was calculated as >40 μM. The disaggregation of pre-
formed fibrils was also investigated by employing TEM.
fAβ42 (20 μM), prepared by incubation at 37°C for three
days showed predominantly fibrils (Figure 6D, left
panel). The fibrils were converted to a smaller aggregates
like shape when incubated in the presence of K-3-rh for
12 h, where dose dependent effects were also observed
(Figure 6D, middle and right panels). This finding indi-
cated that K-3-rh disintegrates fibrils and greatly alters
the fibrilar shaped to smaller aggregates. These data sug-
gest that K-3-rh remodels the soluble oligomers and
preformed fibrils to smaller aggregates. The cytotoxic
properties of these converted aggregates were also mea-
sured by MTT assay. As shown in Figure 6E, higher con-
centrations of K-3-rh cause an effective decreased of
MTT reduction, where 40 μM of the compound wasfound to enhance cell survival by ~20% against both pre-
formed oligomers and mature fibrils. All of these data
are in good agreement with the previous reports show-
ing that polyphenolic flavonoids remodel soluble oligo-
mers and fibrils to less-toxic smaller aggregates [50,51].
Discussion
Flavonoids have been widely reported as neuroprotective
agents in several diseases including Alzheimer’s and Parkin-
son’s diseases. The cytoprotective effects of flavonoids can
be revealed in three levels: antioxidation, anti-Aβ aggrega-
tion, and anti-Aβ induced cell death [52]. Kaempferol and
its related flavonoids have been found to be effective against
Aβ aggregation [44], and oxidative stress [52]. Yet, the cor-
relation of anti-amyloidogenic activity and anti-cytotoxic ef-
fect of these flavonoids remains unclear. In the current
study, several flavonoids were screened for their cytoprotec-
tive effects against Aβ42 peptide and the mechanisms of
anti-amyloidogenic effects were explored using a poly-
phenolic Keamferol related flavone, K-3-rh. Most of the
polyphenolic flavonoids were found to reduce the cytotoxic
effects of Aβ to different extents (Figure 2A and 2B). Here,
we focused on the properties of Aβ42 aggregation and its
relation to cytotoxicity in the presence of K-3-rh in order to
explore the mechanisms of the cytoprotective effects of the
flavonoid, as well as to better understand the aggregation
mechanism of the peptide.
Our findings showed that K-3-rh abrogates cytotoxic
effects of Aβ by hindering its on pathway self-assembly. In
the presence of K-3-rh, the fibrillogenesis and structural
transformation of Aβ peptides were inhibited (Figure 3A-F),
which leads to accumulation of several intermediate spe-
cies (Figure 4A-E). The accumulated species were solu-
ble and relatively smaller in size than toxic oligomers
(Figure 5A), devoid of β-sheet fibrillar form (Figures 3F
and 5B) and less toxic (Figure 5C), indicating that they
might not be the “on pathway” aggregates. The findings are
in good agreement with those of previous studies, where
polyphenol (−)-epigallocatechin gallate and taiwniaflavone
were found to be effective in inhibition of fibrillogenesis of
Aβ by directly binding to the unfolded polypeptides and
promoted formation of unstructured and nontoxic, off
pathway, stable oligomeric structures [39,45]. The K-3-rh
and other related flavonoids used in the current study
probably redirected the Aβ assembly in similar way to form
non toxic off-pathway intermediated structure. The modu-
lation of these aggregates by interaction of K-3-rh, how-
ever, might not be specific to unfolded peptides. Our
results showed that K-3-rh inhibits fibrillogenesis of Aβ42
peptide (Figure 3A-E), suggesting that the compound
might interact with several species during aggregation. The
effective inhibition of Aβ42 fibril extension (Figure 3C and
3D) demonstrates the possibility of binding of K-3-rh to
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Figure 6 Preformed oligomers and fibril remodeling activity of K-3-rh. A. Th-T assay of fresh monomeric Aβ42 as control (white bar), Aβ42
preformed oligomers (gray bar) and Aβ42 preformed oligomers in the presence of 40 μM K-3-rh (black bar) incubated for 0, 12 and 24 h. B. TEM
study of maturation of Aβ42 preformed oligomers (OAβ) in the absence (left and middle panel) or presence of 40 μM of K-3-rh (right panel). C.
Dissolution of preformed Aβ42 fibrils in the presence of different concentrations of K-3-rh. The mature Aβ42 fibrils (20 μM) were incubated in the
absence or presence of 0, 10, 20, 40 and 50 μM of K-3-rh for 6 h. IC50 for fibrils disintegration was found to be > 40 μM. Error bars indicate the
standard deviation of triplicate independent experiments. D. TEM study of fibril disaggregation properties of K-3-rh. Twenty μM fibrillar Aβ42 (fAβ)
was incubated in the absence or presence of 20 and 40 μM of K-3-rh for 12 h and TEM images were obtained. Scale bar is shown at the bottom.
E. Cells were treated with 20 μM of oligomeric (gray bar) or fibrilar (black bar) Aβ42 for 12 h in the absence or presence of 0–50 μM of K-3-rh.
Cell viability was assessed by the MTT reduction assay. Error bars indicate the standard deviation of triplicate independent experiments.
Significantly different from only Aβ42 or 0 flavonoid concentration group indicated as **p < 0.01 for oligomers Aβ and ## p < 0.01 for fibrilar Aβ.
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preventing it from misfolding into the β-sheet conform-
ation (Figure 3F). Aromatic interaction between K-3-rh
and aromatic residues of the Aβ sequence might be a pos-
sible explanation for this inhibitory mechanism. It has been
suggested that inhibitory aromatic compounds compete
with polypeptide monomers for interaction with growing
fibrils, and the irreversible or improved interaction by the
inhibitor results in an efficient halt of the fibrillization
process [53]. Only the phenolic ring by itself, however,
does not efficiently inhibit amyloid formation [54] and
further structural elements are necessary for the specificinteraction with the amyloidogenic β-sheet conform-
ation for creation of hydrogen bonds that enhance the
stability of the inhibitor–protein complex [55]. Struc-
tural composition of K-3-rh includes three phenolic
groups linked with a rhamnose moiety (Figure 1). The
OH groups and rhamnose structure of K-3-rh probably
play a supporting role for efficient interaction with β-
sheet fibrils of Aβ42 and hence abrogates its further as-
sembly by forming a stable K-3-rh –Aβ42 complex.
The maturation of soluble oligomers is an important
event in the Aβ fibrillogenesis pathway. A slight change
of agitation condition during Aβ aggregation can result
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http://www.jbiomedsci.com/content/19/1/104in development of these oligomeric forms to multiple
conformers with different biochemical properties rather
than following a single nucleation pathway [50]. Small
molecules have also been found to convert these soluble
oligomers into significantly different structural confor-
mations [56]. Similar remodeling of soluble oligomers by
K-3-rh into a less toxic smaller Aβ42 conformer was also
noted in the current study (Figure 6A, 6B and 6E). In
addition, K-3-rh was also found to disintegrate mature
fibrils (Figure 6C) with an IC50 value of 40 μM, and to
remodel them into smaller aggregates (Figure 6D) with
less-toxic properties (Figure 6E). From these results, it
seems clear that binding of K-3-rh is not limited to a
specific Aβ conformer. However, the result showing that
the IC50 value of fibril disintegration was higher than
that of fibril extension, suggesting the binding preference
of K-3-rh to non-fibrillar Aβ conformers. Because both
Aβ monomers and soluble oligomers possess similar sec-
ondary structure, which is different from β-sheet fibrillar
structure, modulation of monomeric Aβ and remodeling
of toxic soluble oligomers is expected to occur in a simi-
lar manner. In the current study, both monomeric Aβ
(Figure 4A-E) and soluble oligomeric Aβ (Figure 6B)
were found to convert into smaller aggregates that were
less toxic (Figures 5C and 6E). In addition, effective
disaggregation properties of polyphenolic glycosidic
compounds suggest that glycoside structure is an im-
portant determinant for conversion of low molecular
weight aggregates from prefibrillar oligomers [51,56,57].
In the current study, the rhamnose moiety of K-3-rh
structure may play a partial role in alteration of mono-
mers to low molecular weight soluble non-toxic oligo-
mers (Figures 4A-G and 5A) and preformed oligomers
to smaller aggregates (Figure 6B), while other factors
may be involved in the process. As another mechanistic
approach based on structural similarities between vari-
ous highly efficient polyphenol inhibitors, and relative to
the well-known amyloidogenic dye Congo red, it has
been suggested that common efficient polyphenol inhibi-
tors are composed of at least two phenolic rings with
two to six atom linkers, and a minimum number of three
OH groups on the aromatic rings [55]. These structural
similarities imply three-dimensional conformations that
are essential for the non-covalent interaction with β-sheet
structures [55]. Hence, the non-covalent interaction be-
tween Aβ and K-3-rh might be a good speculation for the
fibrils remodeling properties of this flavonoid.
Conclusion
Identification of small molecule inhibitors for inhibition
of Aβ aggregation and cytotoxicity is an encouraging
approach toward the therapeutic development for treat-
ment of AD. In the current study, we demonstrated that
a mono flavonoid furnished with three OH, threephenolic groups conjugated to a rhamnose moiety is an
effective molecule for alteration of the on pathway ag-
gregation of Aβ peptide to form non-toxic off pathway
conformers. The results support the model of a specific
structural conformation for efficient inhibition of amy-
loidogenic assembly and interaction with β-sheet struc-
ture, as well as effectiveness of polyphenol glycosides in
abrogation of the amyloidogenic properties of Aβ42
peptide. We suggest that polyphenolic compounds with
K-3-rh like structure might be good candidates for in-
corporation into the therapeutic strategy for treatment
of AD.
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